The Latest Breaking News from Biogen

The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

The highly influential paper, first published in 2006, has helped guide billions of dollars in US federal research into the disease

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The SPDR S&P Biotech ETF is the IBD Stock Of The Day. XBI stock has shucked off near-term resistance on enthusiasm for biotech stocks.

The stock market erased early losses to trade higher by midday on the strength of robust earnings from Netflix and others.

The Dow Jones Industrial Average fell Wednesday, as Netflix stock jumped on earnings results. Tesla earnings are due out after the close.

Biogen's second-quarter report was "fine," one analyst said. But without an update on its strategy for life after Aduhelm, Biogen stock fell.

Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.

Biogen's (NASDAQ:BIIB) short percent of float has risen 9.27% since its last report. The company recently reported that it has 2.41 million shares sold short, which is 1.65% of all regular shares that are available for trading.

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.63% on an annualized basis producing an average annual return of 10.11%. Currently, Biogen has a market capitalization of $31.20 billion.